Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCAN-RX-0201
- Development stage
- Preclinical
- Lead developer
- Opus Genetics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LCAN-RX-0201 is a nanoparticle-based delivery system for RX-0201 (archexin), a 20-mer phosphorothioate antisense oligonucleotide that targets Akt-1 (protein kinase B alpha). The formulation consists of lipid-coated albumin nanoparticles (LCAN) composed of DOTAP, soyPC, TPGS, and a human serum albumin-pentaethylenehexamine (HSA-PEHA) conjugate. A folate-targeted version, F-LCAN-RX-0201, incorporates folate-PEG-DSPE to specifically target folate receptor-expressing tumor cells. By encapsulating the antisense agent, the LCAN system improves the pharmacokinetic profile, increases cellular uptake, and enhances the antitumor activity of RX-0201 compared to the free oligonucleotide. It was developed by Rexahn Pharmaceuticals in collaboration with researchers at The Ohio State University.
- Other names
- folate receptor-targeted lipid coated albumin nanoparticles containing RX-0201
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on LCAN-RX-0201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCAN-RX-0201.